$OBLN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ReShape Lifesciences Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ReShape Lifesciences Inc.. Get notifications about new insider transactions in ReShape Lifesciences Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Fisher Douglas | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Fisher Douglas | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Fisher Douglas | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Fisher Douglas | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Option Exercise | A | 0.77 | 27,250 | 20,983 | 27,250 | ||
| Sep 18 2020 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Option Exercise | A | 0.00 | 27,250 | 0 | 27,250 | ||
| Jun 25 2020 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | Chief Financial Off ... | Option Exercise | A | 0.73 | 165,135 | 120,549 | 165,135 | |
| Jun 25 2020 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | Chief Financial Off ... | Option Exercise | A | 0.00 | 52,865 | 0 | 52,865 | |
| Jun 25 2020 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | President, CEO & Ex ... | Option Exercise | A | 0.73 | 165,135 | 120,549 | 165,135 | |
| Jun 25 2020 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | President, CEO & Ex ... | Option Exercise | A | 0.00 | 52,865 | 0 | 52,865 | |
| Jan 28 2020 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CEO | Option Exercise | A | 0.00 | 441,125 | 0 | 441,125 | |
| Jan 28 2020 | OBLN | OBALON THERAPEUTIC ... | MacDonald Robert J | Chief Retail Office ... | Option Exercise | A | 0.00 | 88,225 | 0 | 88,225 | |
| Jan 28 2020 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | Chief Financial Off ... | Option Exercise | A | 0.00 | 88,225 | 0 | 88,225 | |
| Nov 14 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CEO | Buy | P | 1.66 | 65,000 | 107,822 | 106,806 | 41.8 K to 106.8 K (+155.48 %) |
| Nov 14 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CEO | Buy | P | 1.66 | 65,000 | 107,822 | 106,806 | 41.8 K to 106.8 K (+155.48 %) |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 1.75 | 13,000 | 22,750 | 13,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 1.75 | 13,000 | 22,750 | 13,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | A | 1.75 | 10,000 | 17,500 | 10,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | A | 1.75 | 10,000 | 17,500 | 10,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | A | 1.75 | 10,000 | 17,500 | 10,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | A | 1.75 | 10,000 | 17,500 | 10,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | MacDonald Robert J | Chief Retail Office ... | Option Exercise | A | 1.75 | 11,000 | 19,250 | 11,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | Chief Financial Off ... | Option Exercise | A | 1.75 | 9,000 | 15,750 | 9,000 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | Chief Financial Off ... | Option Exercise | A | 1.75 | 11,682 | 20,444 | 11,682 | |
| Oct 28 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CEO | Option Exercise | A | 1.75 | 10,000 | 17,500 | 10,000 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Director | Option Exercise | P | 4.40 | 9,375 | 41,250 | 9,375 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Director | Buy | P | 4.00 | 12,500 | 50,000 | 27,148 | 14.6 K to 27.1 K (+85.34 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | DOMAIN PARTERS VII L P | 10% Owner | Option Exercise | P | 4.40 | 187,500 | 825,000 | 187,500 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | DOMAIN PARTERS VII L P | 10% Owner | Buy | P | 4.00 | 250,000 | 1,000,000 | 813,433 | 563.4 K to 813.4 K (+44.37 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | P | 4.40 | 3,750 | 16,500 | 3,750 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Buy | P | 4.00 | 5,000 | 20,000 | 38,865 | 33.9 K to 38.9 K (+14.76 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | MacDonald Robert J | Chief Retail Office ... | Option Exercise | P | 4.40 | 3,750 | 16,500 | 3,750 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | MacDonald Robert J | Chief Retail Office ... | Buy | P | 4.00 | 5,000 | 20,000 | 5,245 | 245 to 5.2 K (+2,040.82 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Option Exercise | P | 4.40 | 3,750 | 16,500 | 3,750 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Buy | P | 4.00 | 5,000 | 20,000 | 16,340 | 11.3 K to 16.3 K (+44.09 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | Exec Chairman of th ... | Option Exercise | P | 4.40 | 9,375 | 41,250 | 9,375 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | Exec Chairman of th ... | Buy | P | 4.00 | 12,500 | 50,000 | 77,892 | 65.4 K to 77.9 K (+19.12 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CFO | Option Exercise | P | 4.40 | 9,375 | 41,250 | 9,375 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CFO | Buy | P | 4.00 | 12,500 | 50,000 | 41,806 | 29.3 K to 41.8 K (+42.65 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | P | 4.40 | 1,875 | 8,250 | 1,875 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Buy | P | 4.00 | 2,500 | 10,000 | 11,764 | 9.3 K to 11.8 K (+26.99 %) |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Option Exercise | P | 4.40 | 4,687 | 20,623 | 4,687 | ||
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Buy | P | 4.00 | 6,250 | 25,000 | 19,397 | 13.1 K to 19.4 K (+47.54 %) | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Option Exercise | P | 4.40 | 5,625 | 24,750 | 5,625 | ||
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Buy | P | 4.00 | 7,500 | 30,000 | 18,061 | 10.6 K to 18.1 K (+71.02 %) | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | INTERWEST PARTNERS X LP | 10% Owner | Option Exercise | P | 4.40 | 18,750 | 82,500 | 18,750 | |
| Aug 08 2019 | OBLN | OBALON THERAPEUTIC ... | INTERWEST PARTNERS X LP | 10% Owner | Buy | P | 4.00 | 25,000 | 100,000 | 380,224 | 355.2 K to 380.2 K (+7.04 %) |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 0.96 | 35,000 | 33,600 | 35,000 | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Option Exercise | A | 0.96 | 35,000 | 33,600 | 35,000 | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | MOATAZEDI DAVID | Grant | A | 0.00 | 78,125 | 0 | 83,619 | 5.5 K to 83.6 K (+1,422.01 %) | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Grant | A | 0.00 | 78,125 | 0 | 131,459 | 53.3 K to 131.5 K (+146.48 %) | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Fisher Douglas | Grant | A | 0.00 | 78,125 | 0 | 78,125 | 0 to 78.1 K | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Grant | A | 0.00 | 78,125 | 0 | 105,597 | 27.5 K to 105.6 K (+284.38 %) | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Grant | A | 0.00 | 78,125 | 0 | 105,597 | 27.5 K to 105.6 K (+284.38 %) | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | A | 0.96 | 35,000 | 33,600 | 35,000 | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | President & CFO | Option Exercise | A | 0.96 | 300,000 | 288,000 | 300,000 | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | MacDonald Robert J | Chief Retail Office ... | Option Exercise | A | 0.96 | 35,000 | 33,600 | 35,000 | |
| Jul 25 2019 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Director | Grant | A | 0.00 | 78,125 | 0 | 146,470 | 68.3 K to 146.5 K (+114.31 %) |
| Jun 03 2019 | OBLN | OBALON THERAPEUTIC ... | MacDonald Robert J | Chief Retail Office ... | Option Exercise | A | 1.58 | 200,000 | 316,000 | 200,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Option Exercise | A | 2.30 | 100,000 | 230,000 | 100,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Young Donald R | VP of Quality Assur ... | Option Exercise | A | 2.30 | 35,000 | 80,500 | 35,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Option Exercise | A | 2.30 | 50,000 | 115,000 | 50,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | Chief Clinical & Re ... | Option Exercise | A | 2.30 | 100,000 | 230,000 | 100,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Option Exercise | A | 2.30 | 100,000 | 230,000 | 100,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Huang Kelly | Pres & Chief Execut ... | Option Exercise | A | 2.30 | 300,000 | 690,000 | 300,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Option Exercise | A | 2.30 | 35,000 | 80,500 | 35,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | MONDORE ROBERT H JR | VP of Operations | Option Exercise | A | 2.30 | 35,000 | 80,500 | 35,000 | |
| Jan 04 2019 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | Exec Chairman of th ... | Grant | A | 0.00 | 86,957 | 0 | 653,905 | 566.9 K to 653.9 K (+15.34 %) |
| Oct 16 2018 | OBLN | OBALON THERAPEUTIC ... | SCHMIDT DAINA | Vice President of M ... | Option Exercise | A | 2.11 | 60,000 | 126,600 | 60,000 | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Wood Todd Michael | Vice President of S ... | Grant | A | 1.82 | 5,494 | 9,999 | 5,494 | 0 to 5.5 K |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Grant | A | 1.82 | 27,472 | 49,999 | 53,334 | 25.9 K to 53.3 K (+106.23 %) | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Grant | A | 1.82 | 27,472 | 49,999 | 27,472 | 0 to 27.5 K | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Huang Kelly | Pres & Chief Operat ... | Grant | A | 1.82 | 54,945 | 100,000 | 119,945 | 65 K to 119.9 K (+84.53 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 1.82 | 107,142 | 194,998 | 338,634 | 231.5 K to 338.6 K (+46.28 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Grant | A | 1.82 | 32,967 | 60,000 | 113,387 | 80.4 K to 113.4 K (+40.99 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Young Donald R | VP of Quality Assur ... | Grant | A | 1.82 | 2,747 | 5,000 | 24,992 | 22.2 K to 25 K (+12.35 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | VP of Reg. and Clin ... | Grant | A | 1.82 | 10,989 | 20,000 | 92,639 | 81.7 K to 92.6 K (+13.46 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Grant | A | 1.82 | 13,736 | 25,000 | 61,267 | 47.5 K to 61.3 K (+28.90 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | CEO | Grant | A | 1.82 | 109,890 | 200,000 | 566,948 | 457.1 K to 566.9 K (+24.04 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Wood Todd Michael | Vice President of S ... | Grant | A | 1.82 | 5,494 | 9,999 | 5,494 | 0 to 5.5 K |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Grant | A | 1.82 | 27,472 | 49,999 | 293,044 | 265.6 K to 293 K (+10.34 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Grant | A | 1.82 | 27,472 | 49,999 | 53,334 | 25.9 K to 53.3 K (+106.23 %) | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Grant | A | 1.82 | 27,472 | 49,999 | 27,472 | 0 to 27.5 K | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Grant | A | 1.82 | 27,472 | 49,999 | 27,472 | 0 to 27.5 K | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | MOATAZEDI DAVID | Grant | A | 1.82 | 5,494 | 9,999 | 5,494 | 11 K to 5.5 K (-50.00 %) | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Huang Kelly | Pres & Chief Operat ... | Grant | A | 1.82 | 54,945 | 100,000 | 119,945 | 65 K to 119.9 K (+84.53 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | MONDORE ROBERT H JR | VP of Operations | Grant | A | 1.82 | 13,736 | 25,000 | 13,736 | 0 to 13.7 K |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 1.82 | 107,142 | 194,998 | 338,634 | 231.5 K to 338.6 K (+46.28 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Grant | A | 1.82 | 32,967 | 60,000 | 113,387 | 80.4 K to 113.4 K (+40.99 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Young Donald R | VP of Quality Assur ... | Grant | A | 1.82 | 2,747 | 5,000 | 24,992 | 22.2 K to 25 K (+12.35 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | VP of Reg. and Clin ... | Grant | A | 1.82 | 10,989 | 20,000 | 92,639 | 81.7 K to 92.6 K (+13.46 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Grant | A | 1.82 | 13,736 | 25,000 | 61,267 | 47.5 K to 61.3 K (+28.90 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | CEO | Grant | A | 1.82 | 109,890 | 200,000 | 566,948 | 457.1 K to 566.9 K (+24.04 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Grant | A | 1.82 | 27,472 | 49,999 | 293,044 | 265.6 K to 293 K (+10.34 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Grant | A | 1.82 | 27,472 | 49,999 | 27,472 | 0 to 27.5 K | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | MOATAZEDI DAVID | Grant | A | 1.82 | 5,494 | 9,999 | 5,494 | 11 K to 5.5 K (-50.00 %) | |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | MONDORE ROBERT H JR | VP of Operations | Grant | A | 1.82 | 13,736 | 25,000 | 13,736 | 0 to 13.7 K |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Director | Buy | P | 1.82 | 54,945 | 100,000 | 68,345 | 13.4 K to 68.3 K (+410.04 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | DOMAIN PARTERS VII L P | 10% Owner | Buy | P | 1.82 | 1,648,359 | 3,000,013 | 5,634,329 | 4 M to 5.6 M (+41.35 %) |
| Aug 27 2018 | OBLN | OBALON THERAPEUTIC ... | INTERWEST PARTNERS X LP | 10% Owner | Buy | P | 1.82 | 1,098,901 | 2,000,000 | 3,552,239 | 2.5 M to 3.6 M (+44.79 %) |
| Jun 15 2018 | OBLN | OBALON THERAPEUTIC ... | Kamdar Kim P. | Director | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | |
| Jun 14 2018 | OBLN | OBALON THERAPEUTIC ... | Stevenson Sharon | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | ||
| Jun 14 2018 | OBLN | OBALON THERAPEUTIC ... | SHACKNAI JONAH | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | ||
| Jun 14 2018 | OBLN | OBALON THERAPEUTIC ... | HOWE LESLEY H | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | ||
| Jun 14 2018 | OBLN | OBALON THERAPEUTIC ... | Fisher Douglas | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | ||
| Jun 14 2018 | OBLN | OBALON THERAPEUTIC ... | DITTAMORE RAYMOND V | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | ||
| Jun 14 2018 | OBLN | OBALON THERAPEUTIC ... | MOATAZEDI DAVID | Option Exercise | A | 2.36 | 81,774 | 192,987 | 81,774 | ||
| May 17 2018 | OBLN | OBALON THERAPEUTIC ... | Young Donald R | VP of Quality Assur ... | Grant | A | 0.00 | 20,377 | 0 | 20,377 | 0 to 20.4 K |
| May 17 2018 | OBLN | OBALON THERAPEUTIC ... | Hussainy Nooshin | VP of Finance | Grant | A | 0.00 | 21,875 | 0 | 21,875 | 0 to 21.9 K |
| May 17 2018 | OBLN | OBALON THERAPEUTIC ... | Huang Kelly | Chief Operating Off ... | Grant | A | 0.00 | 65,000 | 0 | 65,000 | 0 to 65 K |
| May 17 2018 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | VP of Reg. and Clin ... | Grant | A | 0.00 | 15,000 | 0 | 75,000 | 60 K to 75 K (+25.00 %) |
| May 17 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Grant | A | 0.00 | 17,938 | 0 | 17,938 | 0 to 17.9 K |
| May 17 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Grant | A | 0.00 | 45,000 | 0 | 45,000 | 0 to 45 K |
| May 09 2018 | OBLN | OBALON THERAPEUTIC ... | Wood Todd Michael | Vice President of S ... | Option Exercise | A | 4.30 | 80,000 | 344,000 | 80,000 | |
| May 02 2018 | OBLN | OBALON THERAPEUTIC ... | Rasdal Andrew P | President & CEO | Grant | A | 3.27 | 2,987 | 9,767 | 457,058 | 454.1 K to 457.1 K (+0.66 %) |
| May 02 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Grant | A | 3.27 | 2,743 | 8,970 | 29,593 | 26.9 K to 29.6 K (+10.22 %) |
| May 02 2018 | OBLN | OBALON THERAPEUTIC ... | Brister Mark | Chief Technology Of ... | Grant | A | 3.27 | 2,622 | 8,574 | 166,492 | 163.9 K to 166.5 K (+1.60 %) |
| Apr 04 2018 | OBLN | OBALON THERAPEUTIC ... | MONDORE ROBERT H JR | Option Exercise | A | 3.55 | 60,000 | 213,000 | 60,000 | ||
| Mar 19 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Buy | P | 3.96 | 5,000 | 19,778 | 26,850 | 21.9 K to 26.9 K (+22.88 %) |
| Mar 15 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Buy | P | 4.04 | 5,412 | 21,843 | 15,000 | 9.6 K to 15 K (+56.45 %) |
| Mar 15 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Buy | P | 4.05 | 9,588 | 38,825 | 9,588 | 0 to 9.6 K |
| Mar 15 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Buy | P | 4.04 | 5,300 | 21,387 | 15,000 | 9.7 K to 15 K (+54.64 %) |
| Mar 15 2018 | OBLN | OBALON THERAPEUTIC ... | Plovanic William J. | Chief Financial Off ... | Buy | P | 4.05 | 9,700 | 39,276 | 9,700 | 0 to 9.7 K |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Option Exercise | M | 1.77 | 4,310 | 7,629 | 6,034 | |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Option Exercise | M | 0.76 | 3,641 | 2,767 | 1,083 | |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Option Exercise | M | 1.83 | 5,746 | 10,515 | 0 | |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Option Exercise | M | 1.31 | 229 | 300 | 0 | |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Buy | M | 1.77 | 4,310 | 7,629 | 21,850 | 17.5 K to 21.9 K (+24.57 %) |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Buy | M | 0.76 | 3,641 | 2,767 | 17,540 | 13.9 K to 17.5 K (+26.20 %) |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Buy | M | 1.83 | 5,746 | 10,515 | 13,899 | 8.2 K to 13.9 K (+70.48 %) |
| Feb 05 2018 | OBLN | OBALON THERAPEUTIC ... | Drake Neil | VP Research and Dev ... | Buy | M | 1.31 | 229 | 300 | 8,153 | 7.9 K to 8.2 K (+2.89 %) |
| Jan 30 2018 | OBLN | OBALON THERAPEUTIC ... | VandenBerg Amy | VP of Reg. and Clin ... | Option Exercise | M | 1.31 | 1,541 | 2,019 | 0 |